Status
Conditions
Treatments
About
The purpose of this study is to see if lobucavir is a safe and effective treatment for cytomegalovirus in patients with AIDS.
Full description
Patients receive 1 of 2 doses of lobucavir for 28 days, with 2 weeks of follow-up. Weekly clinic visits are required.
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Inclusion Criteria
Concurrent Medication:
Allowed:
Patients must have:
Exclusion Criteria
Co-existing Condition:
Patients with the following symptoms or conditions are excluded:
Patients with the following prior conditions are excluded:
Prior Medication:
Excluded within 4 weeks prior to study entry:
Prior Treatment:
Excluded within 4 weeks prior to study entry:
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal